The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Open accessAbstract
BACKGROUND: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. METHODS: We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). RESULTS: All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. CONCLUSIONS: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,082
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana, M., Hacein‐Bey‐Abina, S., Basile, G. D. S., Gross, F., Yvon, E. S., Nusbaum, P., Selz, F., Hue, C., Dogniaux, S., Casanova, J., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,685
Self-citationAkaike's Information Criterion in Generalized Estimating Equations
Pan, W. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00120.x · Cited by 2,545
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationGeneralized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766
Noguchi, M. (1993) · Cell · doi:10.1016/0092-8674(93)90167-o · Cited by 1,338
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citation
Research works printed but not linked: 2
- Gaspar HB, 2011, Sci Transl Med, 3, 97ra79
- Coffin JM, Hughes SH, Varmus HE. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997.
Cited by
Sorted by citations
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationHematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Self-citationHigh, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome
Hacein‐Bey‐Abina, S., Gaspar, H. B., Blondeau, J., Caccavelli, L., Charrier, S., Buckland, K. F., Pïcard, C., Six, E. M., Himoudi, N., Gilmour, K. C., et al. (2015) · JAMA · doi:10.1001/jama.2015.3253 · Cited by 391
Self-citationThe γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J., & O’Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 385
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 365
Human inborn errors of immunity: An expanding universe
Notarangelo, L. D., Bacchetta, R., Casanova, J., & Su, H. C. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1662 · Cited by 294
Self-citationLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
Ravin, S. S. D., Wu, X., Moir, S. L., Kardava, L., Anaya‐O’Brien, S., Kwatemaa, N., Littel, P. L., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 284
Self-citationIntegration site selection by retroviruses and transposable elements in eukaryotes
Sultana, T., Zamborlini, A., Cristofari, G., & Lesage, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.7 · Cited by 275
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., Coppi, P. D., Culme-Seymour, E. J., Gibbon, S. E., Hitchcock, J., Mason, C., Montgomery, J., Stephen Morris, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 285
Self-citationLentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S. J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815408 · Cited by 263
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 273
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 263
Self-citationHematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.10.010 · Cited by 252
Self-citationAdvantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloeß, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 247
Self-citationGene Insertion Into Genomic Safe Harbors for Human Gene Therapy
Papapetrou, E. P., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.38 · Cited by 238
Self-citationClinical development of gene therapy: results and lessons from recent successes
Kumar, S. R. P., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 246
Human RAG mutations: biochemistry and clinical implications
Notarangelo, L. D., Kim, M., Walter, J. E., & Lee, Y. N. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.28 · Cited by 241
Self-citationLesbats, P., Engelman, A., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 250
Severe combined immunodeficiencies and related disorders
Fischer, A., Notarangelo, L. D., Neven, B., Cavazzana, M., & Puck, J. M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.61 · Cited by 226
Self-citationSchiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R. E., Eggan, K. C., Gao, G., Gil-Fariña, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 222
Self-citationGene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André‐Schmutz, I., & Six, E. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 205
Self-citationViral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. H. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 208
Biomanufacturing for clinically advanced cell therapies
Aijaz, A., Li, M., Smith, D. W., Khong, D., LeBlon, C. E., Fenton, O. S., Olabisi, R. M., Libutti, S. K., Tischfield, J. A., Maus, M. V., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0246-6 · Cited by 198
Self-citationGene correction for SCID-X1 in long-term hematopoietic stem cells
Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., Lee, C. M., Bao, G., Kildebeck, E., Punjya, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09614-y · Cited by 193
Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations
Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., Kiem, H., & Adair, J. E. (2019) · Nature Materials · doi:10.1038/s41563-019-0385-5 · Cited by 158
Nassi, J. J., Cepko, C. L., Born, R. T., & Beier, K. T. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00080 · Cited by 161
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Duncan, C., Bledsoe, J. R., Grzywacz, B. J., Beckman, A., Bonner, M. A., Eichler, F., Kühl, J., Harris, M. H., Slauson, S. R., Colvin, R. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405541 · Cited by 161
Self-citationBushman, F. D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.009 · Cited by 160
Self-citationLin, J., & Leonard, W. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041447 · Cited by 150
Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G., & Aiuti, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28762-2 · Cited by 149
BTK Signaling in B Cell Differentiation and Autoimmunity
Corneth, O. B. J., Wolterink, R. G. J. K., & Hendriks, R. W. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_478 · Cited by 145
Gene Therapy 2017: Progress and Future Directions
Keeler, A. M., ElMallah, M. K., & Flotte, T. R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12466 · Cited by 147
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 137
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 141
Gene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 145
Self-citationINSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes
Sherman, E. A., Nobles, C. L., Berry, C. C., Six, E. M., Wu, Y., Dryga, A., Malani, N., Male, F., Reddy, S. G., Bailey, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.002 · Cited by 128
Self-citationGene Therapy with the Sleeping Beauty Transposon System
Kebriaei, P., Izsvák, Z., Narayanavari, S. A., Singh, H., & Ivics, Z. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.008 · Cited by 128
Hickman, A. B., & Dyda, F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00003 · Cited by 123
Gene therapy for sickle cell disease: An update
Demirci, S., Uchida, N., & Tisdale, J. F. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.04.003 · Cited by 126
History and current status of newborn screening for severe combined immunodeficiency
Kwan, A., & Puck, J. M. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.03.004 · Cited by 119
Chang, C., Lai, Y.-S., Westin, E. R., Khodadadi‐Jamayran, A., Pawlik, K. M., Lamb, L. S., Goldman, F. D., & Townes, T. M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.013 · Cited by 115
Treating Immunodeficiency through HSC Gene Therapy
Booth, C., Gaspar, H. B., & Thrasher, A. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.002 · Cited by 110
Self-citationGene therapy for severe combined immunodeficiencies and beyond
Fischer, A., & Hacein‐Bey‐Abina, S. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190607 · Cited by 108
Self-citationGene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
Self-citationSevere Combined Immunodeficiency Disorders
Chinn, I. K., & Shearer, W. T. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.07.002 · Cited by 93
Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9
Stephens, C. J., Lauron, E. J., Kashentseva, E. A., Lu, Z. H., Yokoyama, W. M., & Curiel, D. T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.009 · Cited by 89
Dorsey, M. J., Dvorak, C. C., Cowan, M. J., & Puck, J. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.005 · Cited by 88
INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions
Berry, C. C., Nobles, C. L., Six, E. M., Wu, Y., Malani, N., Sherman, E. A., Dryga, A., Everett, J. K., Male, F., Bailey, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.003 · Cited by 89
Self-citationProspective neonatal screening for severe T‐ and B‐lymphocyte deficiencies in Seville
de Felipe, B., Olbrich, P., Lucenas, J., Delgado‐Pecellín, C., Delgado, A. P., Marquez, J., Salamanca, C., Soler‐Palacín, P., González‐Granado, L. I., Ferreras-Antolin, L., et al. (2015) · Pediatric Allergy and Immunology · doi:10.1111/pai.12501 · Cited by 84
Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies
Abraham, R. S., & Aubert, G. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00001-16 · Cited by 83
Primary Immune Deficiency Treatment Consortium (PIDTC) report
Griffith, L. M., Cowan, M. J., Notarangelo, L. D., Kohn, D. B., Puck, J. M., Pai, S., Ballard, B., Bauer, S. C., Bleesing, J., Boyle, M., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.052 · Cited by 83
Self-citationClinical Applications of Gene Therapy for Primary Immunodeficiencies
Cicalese, M. P., & Aiuti, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.047 · Cited by 80
Touzot, F., Moshous, D., Creidy, R., Neven, B., Frange, P., Cros, G., Caccavelli, L., Blondeau, J., Magnani, A., Luby, J.-M., et al. (2015) · Blood · doi:10.1182/blood-2014-12-616003 · Cited by 75
Self-citationEvolving Gene Therapy in Primary Immunodeficiency
Thrasher, A. J., & Williams, D. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.018 · Cited by 77
Self-citationGene Therapies for Primary Immune Deficiencies
Kohn, L. A., & Kohn, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648951 · Cited by 75
Self-citationBrendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
Self-citationLymphoid Regeneration from Gene-Corrected SCID-X1 Subject-Derived iPSCs
Menon, T., Firth, A. L., Scripture-Adams, D. D., Galić, Z., Qualls, S. J., Gilmore, W. B., Ke, E., Singer, O., Anderson, L., Bornzin, A. R., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.005 · Cited by 71
Severe combined immunodeficiency: recent developments and guidance on clinical management
Rivers, L., & Gaspar, H. B. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2014-306425 · Cited by 70
Self-citationLi, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-0134-z · Cited by 68
Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect
Chen, C., Yue, D., Lei, L., Wang, H., Lu, J., Zhou, Y., Liu, S., Ding, T., Guo, M., & Xu, L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.003 · Cited by 66
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Chapman, M. S., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 66
Self-citationDelivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
Gene Therapy for the Treatment of Primary Immune Deficiencies
Kuo, C. Y., & Kohn, D. B. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0615-8 · Cited by 66
Self-citationGene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 64
Self-citationBenati, D., Miselli, F., Cocchiarella, F., Patrizi, C., Carretero, M., Baldassarri, S., Ammendola, V., Has, C., Colloca, S., Río, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.024 · Cited by 64
Gene therapy for primary immunodeficiency
Booth, C., Romano, R., Roncarolo, M. G., & Thrasher, A. J. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz170 · Cited by 63
Self-citationGene therapy for primary immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., Touzot, F., & Cavazzana, M. (2015) · Clinical Genetics · doi:10.1111/cge.12576 · Cited by 65
Self-citationLentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Srivastava, A., Abraham, A., Aboobacker, F. N., Singh, G., Geevar, T., Kulkarni, U. P., Selvarajan, S., Korula, A., Dave, R. G., Shankar, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2410597 · Cited by 60
Ghosh, S., Carmo, M., Calero-Garcia, M., Ricciardelli, I., Bustamante‐Ogando, J. C., Blundell, M. P., Schambach, A., Ashton‐Rickardt, P. G., Booth, C., Ehl, S. R., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.050 · Cited by 59
Self-citationTherapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients
Díez, B., Genovese, P., Roman‐Rodriguez, F. J., Alvarez, L. A., Schiroli, G., Ugalde, L., Rodríguez, S., Sevilla, J., de Heredia, C. D., Holmes, M. C., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707540 · Cited by 59
Gene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
Self-citationPaying for future success in gene therapy
Orkin, S. H., & Reilly, P. R. (2016) · Science · doi:10.1126/science.aaf4770 · Cited by 59
Hoffmann, D., Schott, J. W., Geis, F. K., Lange, L., Müller, F.-J., Lenz, D., Zychlinski, D., Steinemann, D., Morgan, M. A., Moritz, T., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.20 · Cited by 58
Self-citationAl–Herz, W., Chou, J. S., Delmonte, O. M., Massaad, M. J., Bainter, W., Castagnoli, R., Klein, C., Bryceson, Y. T., Geha, R. S., & Notarangelo, L. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03146 · Cited by 56
Self-citationThe Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy
Bernardo, M. E., & Aiuti, A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.103 · Cited by 56
Rı́o, P., Navarro, S., Güenechea, G., Sánchez‐Domínguez, R., Lamana, M. L., Yañez, R., Casado, J. A., Mehta, P. A., Pujol, R. M., Surrallés, J., et al. (2017) · Blood · doi:10.1182/blood-2017-03-774174 · Cited by 59
Long-term lineage commitment in haematopoietic stem cell gene therapy
Calabria, A., Spinozzi, G., Cesana, D., Buscaroli, E., Benedicenti, F., Pais, G., Gazzo, F., Scala, S., Lidonnici, M. R., Scaramuzza, S., et al. (2024) · Nature · doi:10.1038/s41586-024-08250-x · Cited by 55
Gene therapy for inborn errors of immunity: past, present and future
Fischer, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00800-6 · Cited by 54
Self-citationHistoric Overview of Genetic Engineering Technologies for Human Gene Therapy
Tamura, R., & Toda, M. (2020) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2020-0049 · Cited by 52
Gene therapy for monogenic disorders of the bone marrow
Ghosh, S., Thrasher, A. J., & Gaspar, H. B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13520 · Cited by 53
Self-citationPoletti, V., Charrier, S., Corre, G., Gjata, B., Vignaud, A., Zhang, F., Rothe, M., Schambach, A., Gaspar, H. B., Thrasher, A. J., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.002 · Cited by 51
Self-citationSchott, J. W., León‐Rico, D., Ferreira, C. B., Buckland, K. F., Santilli, G., Armant, M. A., Schambach, A., Cavazza, A., & Thrasher, A. J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.015 · Cited by 54
Self-citationDerakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Evolution of Gene Therapy, Historical Perspective
Malech, H. L., Garabedian, E., & Hsieh, M. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.001 · Cited by 51
Viral vectors for gene therapy and gene modification approaches
Merten, O., & Gaillet, B. (2015) · Biochemical Engineering Journal · doi:10.1016/j.bej.2015.09.005 · Cited by 50
Newborn Screening for Severe Combined Immunodeficiency in Taiwan
Chien, Y., Yu, H., Lee, N., Ho, H., Kao, S.-M., Lu, M., Jaing, T., Lee, W., Chang, K.-W., Shieh, C.-C. K., et al. (2017) · International Journal of Neonatal Screening · doi:10.3390/ijns3030016 · Cited by 47
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS
Swamy, M. N., Wu, H., & Shankar, P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.005 · Cited by 51
New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing
Kohn, D. B., & Kuo, C. Y. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.007 · Cited by 48
Self-citationPrimary Immune Deficiency Treatment Consortium (PIDTC) update
Griffith, L. M., Cowan, M. J., Notarangelo, L. D., Kohn, D. B., Puck, J. M., Shearer, W. T., Burroughs, L. M., Torgerson, T. R., Decaluwe, H., & Haddad, É. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.01.051 · Cited by 46
Self-citationKao, R. L., Truscott, L. C., Chiou, T., Tsai, W. K., Wu, A. M., & Oliveira, S. N. D. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.180 · Cited by 49
Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer
Baruteau, J., Perocheau, D. P. B., Hanley, J., Lorvellec, M., Rocha‐Ferreira, E., Karda, R., Ng, J., Suff, N., Diaz, J. F. A., Rahim, A. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05972-1 · Cited by 45
Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 47
Blanco, E., Izotova, N., Booth, C., & Thrasher, A. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608653 · Cited by 45
Self-citationAdeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 43
Bernadin, O., Amirache, F., Girard-Gagnepain, A., Moirangthem, R. D., Lévy, C., Ma, K., Costa, C., Négre, D., Reimann, C., Fenard, D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027508 · Cited by 44
Self-citation
Metadata
- Authors
- Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., Caccavelli, L., Cros, G., De Oliveira, S., Fernández, K. S., Guo, D., Harris, C. E., Hopkins, G., Lehmann, L. E., Lim, A., London, W. B., van der Loo, J. C. M., Malani, N., Male, F., Malik, P., Marinovic, M. A., McNicol, A.-M., Moshous, D., Neven, B., Oleastro, M., Picard, C., Ritz, J., Rivat, C., Schambach, A., Shaw, K. L., Sherman, E. A., Silberstein, L. E., Six, E., Touzot, F., Tsytsykova, A., Xu-Bayford, J., Baum, C., Bushman, F. D., Fischer, A., Kohn, D. B., Filipovich, A. H., Notarangelo, L. D., Cavazzana, M., Williams, D. A., & Thrasher, A. J.
- Affiliations
- Boston Children's Hospital (US)
- Great Ormond Street Hospital (GB)
- Cincinnati Children's Hospital Medical Center (US)
- Inserm (FR)
- University College London (GB)
- Peoria campus of the University of Illinois System (US)
- Institut Pasteur (FR)
- University of Pennsylvania (US)
- Clinica Santa Maria (CL)
- Sorbonne Paris Cité (FR)
- Garrahan Hospital (AR)
- Medizinische Hochschule Hannover (DE)
- University of California, Los Angeles (US)
- Harvard University (US)
- ORCID
- Pai, Sung-Yun
- Gaspar, H. Bobby
- Armant, Myriam
- Bleesing, Jack
- Buckland, Karen F.
- Caccavelli, Laure
- Cros, Guilhem
- Fernández, Karen S.
- Harris, Chad E.
- Lehmann, Leslie E.
- London, Wendy B.
- Malani, Nirav
- Malik, Punam
- Moshous, Despina
- Ritz, Jerome
- Schambach, Axel
- Shaw, Kit L.
- Sherman, Eric A.
- Silberstein, Leslie E.
- Six, Emmanuelle
- Touzot, Fabien
- Tsytsykova, Alla
- Bushman, Frederic D.
- Fischer, Alain
- Kohn, Donald B.
- Notarangelo, Luigi D.
- Cavazzana, Marina
- Williams, David A.
- Thrasher, Adrian J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-10-09
- Volume
- 371
- Issue
- 15
- Pages
- 1407-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4274995
- OpenAlex
- W2149628283
- Cited by
- 412
- References
- 46
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 17 · 2023: 26 · 2022: 30 · 2021: 17 · 2020: 42 · 2019: 48 · 2018: 36 · 2017: 57 · 2016: 46 · 2015: 56 · 2014: 4
- FWCI
- 35.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0611-10001)
- National Heart, Lung, and Blood Institute (P01HL073104, HL073104, HHSN268201000009C)
- National Institute of Allergy and Infectious Diseases (U01AI087628, R01AI082020, P30AI045008, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- X-linked severe combined immunodeficiency, interleukin-2 receptor gamma chain, LMO2, MECOM, gene therapy, CD34+ hematopoietic stem cells, T cell reconstitution, adenovirus infection
- MeSH terms
- Animals, Genetic Vectors, Humans, Infant, Male, Mutation, T-Lymphocytes, Transduction, Genetic, Genetic Therapy, Gene Expression, Gammaretrovirus, DNA, Complementary, Antigens, CD34, Transgenes, Gene Silencing, Mice, Interleukin Receptor Common gamma Subunit, X-Linked Combined Immunodeficiency Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
